Synaptic Activity Fires Up Antioxidant Defenses
How long a cell survives often depends on just how sturdy its defenses are against reactive oxygen species...
6366 RESULTS
Sort By:
How long a cell survives often depends on just how sturdy its defenses are against reactive oxygen species...
On March 13, Alzheimer disease activist groups met with representatives from the FDA, clinicians, and industry leaders to discuss ways to improve clinical trials for candidate AD drugs...
For a worm, just a few neurons are sufficient to hold a lifetime of memories, making this simple organism an attractive model for learning about learning...
Researchers report that RAGE mediates the toxic effects of Aβ oligomers in entorhinal cortex neurons...
The sixth annual Drug Discovery for Neurodegeneration meeting convened in Washington, DC, on 4-5 February...
This is the second and final part of our coverage of the Drug Discovery for Neurodegeneration meeting, held in Washington, DC, on 4-5 February...
Scientists took a step closer to a stem cell treatment for neurodegenerative disease this week...
With the help of simple model organisms, two research groups have come up with dozens of genes that could be tied to pathological events in two major neurodegenerative diseases...
Consider it the final nail. That’s what coauthor Bill Klunk calls a new study in which he and colleagues show direct correlation between postmortem amyloid pathology and live brain imaging using Pittsburgh Compound B (PIB)...
Can sirtuins do no wrong? These NAD+-dependent deacetylases regulate metabolism, keep mitochondria happy, and increase longevity in animals...
Researchers find that mice expressing SOD1 mutations associated with inherited forms of amyotrophic lateral sclerosis (ALS) show vascular defects early in life...
Aβ is infamous for its ability to form large fibrils rich in β-sheet secondary structure...
Overexpressing a single anti-apoptotic protein on top of an already triple-transgenic model of Alzheimer disease (AD) rescues amyloid and tau pathology...
Companies large and small are targeting amyloid-β (Aβ), guided by the hypothesis that if they can decrease its concentration in the brain, then they will slow down disease...
Having one parent with Alzheimer disease is hard enough; having two must be devastating...